Van Strum & Towne Inc. Sells 2,800 Shares of Pfizer, Inc. (PFE)
Van Strum & Towne Inc. cut its position in shares of Pfizer, Inc. (NYSE:PFE) by 4.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 64,711 shares of the biopharmaceutical company’s stock after selling 2,800 shares during the period. Van Strum & Towne Inc.’s holdings in Pfizer were worth $2,214,000 as of its most recent filing with the SEC.
A number of other hedge funds have also bought and sold shares of the stock. Patriot Financial Group Insurance Agency LLC purchased a new stake in shares of Pfizer during the fourth quarter worth $365,000. Access Financial Services Inc. purchased a new stake in shares of Pfizer during the fourth quarter worth $1,034,000. Israel Discount Bank of New York GFN purchased a new stake in shares of Pfizer during the fourth quarter worth $639,000. Dodge & Cox purchased a new stake in shares of Pfizer during the fourth quarter worth $24,262,000. Finally, River & Mercantile Asset Management LLP purchased a new stake in shares of Pfizer during the fourth quarter worth $7,519,000. 69.09% of the stock is owned by hedge funds and other institutional investors.
Shares of Pfizer, Inc. (NYSE PFE) traded up 1.14% during trading on Thursday, reaching $33.83. 6,028,136 shares of the company’s stock traded hands. The company has a market cap of $201.20 billion, a price-to-earnings ratio of 24.75 and a beta of 1.00. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $35.18. The company’s 50-day moving average is $33.25 and its 200 day moving average is $33.42.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.64 earnings per share. Equities analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be paid a dividend of $0.32 per share. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a dividend yield of 3.83%. Pfizer’s dividend payout ratio is currently 94.12%.
COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.watchlistnews.com/van-strum-towne-inc-sells-2800-shares-of-pfizer-inc-pfe/1534420.html.
A number of brokerages have recently weighed in on PFE. BidaskClub raised shares of Pfizer from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. Credit Suisse Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $38.00 to $36.00 in a report on Thursday, July 20th. Sanford C. Bernstein reaffirmed a “buy” rating and set a $37.00 price target on shares of Pfizer in a report on Wednesday, May 3rd. Barclays PLC reaffirmed a “buy” rating and set a $38.00 price target on shares of Pfizer in a report on Wednesday, May 3rd. Finally, Cowen and Company set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, July 10th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $37.61.
In other news, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the transaction, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 120,014 shares of company stock worth $4,062,493. Insiders own 0.06% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.